Clearmind Applies for Patent to Treat Obesity and Metabolic Syndrome
Patent Application, Based on Research at the Hebrew University, is Latest Result of Ongoing Collaboration with SciSparc Ltd.
VANCOUVER, Sept. 22, 2022 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the “Company“), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced it has filed a provisional patent application related to metabolic syndromes including obesity.
The patent application is another result of the company’s ongoing collaboration with SciSparc Ltd. (NASDAQ: SPRC) (“SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, and with the Hebrew University of Jerusalem.
The patent application is the third application resulting from the collaboration with SciSparc, referring to the proprietary combination of Clearmind’s MEAI, a novel proprietary psychedelic treatment for various addictions, and SciSparc’s Palmitoylethanolamide (PEA), the active ingredient of its proprietary CannAmide™, which is used for treating obesity and its related metabolic disorders.
“Food addiction and obesity are an epidemic raging in the United States and around the world, yet there are few safe and effective anti-obesity treatments on the market,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.
“In pre-clinical studies MEAI has shown great potential in its ability to treat different addictions. Certain metabolic syndromes Can be associated to addictive behaviors, and we believe combining MEAI with SciSparc’s CannAmide™ may create a valuable tool for treating these conditions.”
The study was conducted as part of Clearmind’s research and development projects with the Hebrew University’s Obesity and Metabolism Laboratory, which is led by Joseph Tam, D.M.D., Ph.D., Associate Professor of Pharmacology at the University’s Institute for Drug Research.
“This new patent application continues Clearmind’s strategy since inception to enhance its IP portfolio to create state-of-the-art psychedelic drug candidates, to better serve patients in need,” said Dr. Zuloff-Shani.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of six patent families. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol “CMND“, the Frankfurt Stock Exchange under the symbol “CWYO” and on the OTC Markets under the symbol “CMNDF“.
For further information, please contact:
Investor Relations,
Email: invest@clearmindmedicine.com
Telephone: (604) 260-1566
General Inquiries,
Info@Clearmindmedicine.com
www.Clearmindmedicine.com
FORWARD-LOOKING STATEMENTS:
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company’s business strategy. There is no certainty that any of these events will occur. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any province in which such offer, solicitation or sale would be unlawful. The securities issued, or to be issued, under the Private Placement have not been, and will not be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
Neither the Canadian Securities Exchange (the “CSE”) nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
